Moleculin Biotech’s (MBRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note published on Monday morning,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock. HC Wainwright also issued estimates for Moleculin Biotech’s Q4 2024 earnings at ($1.33) EPS and FY2025 earnings at ($3.31) EPS.

A number of other research analysts have also recently weighed in on the stock. StockNews.com assumed coverage on shares of Moleculin Biotech in a research note on Tuesday, February 25th. They set a “sell” rating for the company. Maxim Group cut shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th.

Moleculin Biotech Price Performance

Shares of MBRX opened at $1.16 on Monday. The firm has a 50 day simple moving average of $1.50 and a 200-day simple moving average of $2.13. Moleculin Biotech has a 1-year low of $0.40 and a 1-year high of $10.35.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.